Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide

In the REWIND trial, dulaglutide reduced cardiovascular (CV) risk versus placebo in patients with type 2 diabetes in both the “established CV disease” (CVD) and “CV risk factor” subgroups. The SUSTAIN 6 and PIONEER 6 trials of semaglutide used different criteria for established CVD from those used i...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Diabetes Obes Metab
Main Authors: Verma, Subodh, Fainberg, Udi, Husain, Mansoor, Rasmussen, Søren, Rydén, Lars, Ripa, Maria Sejersten, Buse, John B.
Formato: Artigo
Idioma:Inglês
Publicado: Blackwell Publishing Ltd 2021
Assuntos:
Brief Reports
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8251906/
https://ncbi.nlm.nih.gov/pubmed/33606902
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14360
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares